Compare NPCE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | TRDA |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.8M | 500.4M |
| IPO Year | 2021 | 2021 |
| Metric | NPCE | TRDA |
|---|---|---|
| Price | $18.73 | $6.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $18.33 | ★ $21.00 |
| AVG Volume (30 Days) | 150.8K | ★ 356.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $99,986,000.00 | $25,421,000.00 |
| Revenue This Year | $0.90 | $39.97 |
| Revenue Next Year | $24.46 | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $7.56 | $4.93 |
| 52 Week High | $19.40 | $16.45 |
| Indicator | NPCE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.58 | 26.90 |
| Support Level | $15.01 | $5.53 |
| Resistance Level | N/A | $6.88 |
| Average True Range (ATR) | 0.86 | 1.02 |
| MACD | 0.17 | -0.65 |
| Stochastic Oscillator | 75.96 | 9.89 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.